<DOC>
	<DOCNO>NCT01731002</DOCNO>
	<brief_summary>Double-masked , randomize , multi-center , dose-response , active-controlled parallel-comparison Netarsudil ( AR-13324 ) latanoprost</brief_summary>
	<brief_title>A Phase 2 , Double-masked , Randomized , Multi-center , Active-controlled , Dose-response Parallel-group Study Comparing Safety Ocular Hypotensive Efficacy Netarsudil ( AR-13324 ) Latanoprost Patients With Elevated Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) IOP ≥ 24 mm Hg 2 eligibility visit ( 08:00 hr ) , 27 day part , ≥ 22 mm Hg 10:00 16:00 hrs second qualification visit . If one eye meet IOP criterion must eye meet criteria qualification timepoints . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Ophthalmic 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure narrow angle . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . IOP &gt; 36 mm Hg . 3 . Known hypersensitivity component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . 4 . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( , e.g. , laser trabeculoplasty ) . 5 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . 6 . Ocular trauma within past six month , ocular surgery laser treatment within past three month prior screen . 7 . Evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis screening ( Visit 0 ) , history herpes simplex keratitis 8 . Ocular medication kind within 30 day Visit 0 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 0 ) c ) lubricate drop dry eye ( may use throughout study ) . 9 . Clinically significant ocular disease ( e.g . uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( i.e. , cupdisc ratio &gt; 0.8 ) . 10 . Central corneal thickness great 600 µm . 11 . Any abnormality prevent reliable applanation tonometry either eye . Systemic : 12 . Clinically significant abnormality ( determine treat physician ) laboratory test screen . 13 . Known hypersensitivity contraindication latanoprost . 14 . Clinically significant systemic disease ( e.g. , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 15 . Participation investigational study within 30 day prior screen . 16 . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . 17 . Due current status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>